A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).

doi:10.1016/j.lungcan.2014.08.019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2014

Matsumoto Yoshifumi, Maemondo Makoto, Ishii Yoshiki, Okudera Koichi, Demura Yoshiki, Takamura Kei, Kobayashi Kunihiko, Morikawa Naoto, Gemma Akihiko, Ishimoto Osamu, Usui Kazuhiro, Harada Masao, Miura Satoru, Fujita Yuka, Sato Ikuro, Saijo Yasuo

Abstract excerpt

OBJECTIVES: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are particularly effective in non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations. However, some studies have reported survival benefits in NSCLC patients with wild-type EGFR upon erlotinib treatment. This trial was conducted to evaluate the efficacy of erlotinib monotherapy and investigate the predictive values...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatocyte Growth Factor

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Share to ras Proteins

Share to Retreatment

Source

Open in PubMed

Identifiers

PMID: 25249428
DOI: 10.1016/j.lungcan.2014.08.019

Genes

EGFR
HGF
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).PMID 25249428Read ↗

A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.Semantic proximity Read ↗

EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.Semantic proximity Read ↗

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.Semantic proximity Read ↗

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Recetor mutation study for 5 years, in a population of patients with non-small cell lung cancerSemantic proximity Read ↗

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.Semantic proximity Read ↗

Non-small cell lung cancer-smokers or non-smokers, does it matter?Semantic proximity Read ↗

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.Semantic proximity Read ↗

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.Semantic proximity Read ↗

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.Semantic proximity Read ↗

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.